JP2024512255A - 部分性脂肪萎縮症を診断および処置するための方法 - Google Patents

部分性脂肪萎縮症を診断および処置するための方法 Download PDF

Info

Publication number
JP2024512255A
JP2024512255A JP2023550240A JP2023550240A JP2024512255A JP 2024512255 A JP2024512255 A JP 2024512255A JP 2023550240 A JP2023550240 A JP 2023550240A JP 2023550240 A JP2023550240 A JP 2023550240A JP 2024512255 A JP2024512255 A JP 2024512255A
Authority
JP
Japan
Prior art keywords
chain variable
variable region
fat percentage
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023550240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512255A5 (enExample
Inventor
ウェンジュン チェン
チャールズ ハリス
ブレット ムッサー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2024512255A publication Critical patent/JP2024512255A/ja
Publication of JP2024512255A5 publication Critical patent/JP2024512255A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4869—Determining body composition
    • A61B5/4872—Body fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/482—Diagnostic techniques involving multiple energy imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
    • A61B6/5217—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data extracting a diagnostic or physiological parameter from medical diagnostic data
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Data Mining & Analysis (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biotechnology (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Artificial Intelligence (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dentistry (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Evolutionary Computation (AREA)
JP2023550240A 2021-02-22 2022-02-22 部分性脂肪萎縮症を診断および処置するための方法 Pending JP2024512255A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163152100P 2021-02-22 2021-02-22
US63/152,100 2021-02-22
PCT/US2022/017222 WO2022178382A1 (en) 2021-02-22 2022-02-22 Method for diagnosing and treating partial lipodystrophy

Publications (2)

Publication Number Publication Date
JP2024512255A true JP2024512255A (ja) 2024-03-19
JP2024512255A5 JP2024512255A5 (enExample) 2025-02-13

Family

ID=80683255

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023550240A Pending JP2024512255A (ja) 2021-02-22 2022-02-22 部分性脂肪萎縮症を診断および処置するための方法

Country Status (14)

Country Link
US (1) US20240153638A1 (enExample)
EP (1) EP4294257B1 (enExample)
JP (1) JP2024512255A (enExample)
DK (1) DK4294257T3 (enExample)
ES (1) ES3055018T3 (enExample)
FI (1) FI4294257T3 (enExample)
HR (1) HRP20251599T1 (enExample)
LT (1) LT4294257T (enExample)
PL (1) PL4294257T3 (enExample)
PT (1) PT4294257T (enExample)
RS (1) RS67523B1 (enExample)
SI (1) SI4294257T1 (enExample)
SM (1) SMT202500444T1 (enExample)
WO (1) WO2022178382A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
SMT202500283T1 (it) * 2018-04-06 2025-09-12 Regeneron Pharma Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AJLUNI ET AL.: "Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort", CLINICAL ENDOCRINOLOGY, vol. 86, JPN6026012947, 2017, pages 698 - 707, ISSN: 0005828940 *
AKINCI ET AL.: "The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin w", JOURNAL OF THE ENDOCRINE SOCIETY, vol. 4, JPN7026001417, 2020, pages 544, ISSN: 0005911263 *

Also Published As

Publication number Publication date
PL4294257T3 (pl) 2026-02-09
ES3055018T3 (en) 2026-02-09
SMT202500444T1 (it) 2026-01-12
PT4294257T (pt) 2025-11-28
FI4294257T3 (fi) 2025-12-19
LT4294257T (lt) 2025-12-29
US20240153638A1 (en) 2024-05-09
HRP20251599T1 (hr) 2026-01-30
WO2022178382A1 (en) 2022-08-25
RS67523B1 (sr) 2026-01-30
EP4294257B1 (en) 2025-11-05
DK4294257T3 (da) 2025-12-08
EP4294257A1 (en) 2023-12-27
SI4294257T1 (sl) 2026-01-30

Similar Documents

Publication Publication Date Title
JP6515168B2 (ja) Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
Schmidt et al. Pemphigoid diseases
EP4294257B1 (en) Method for diagnosing and treating partial lipodystrophy
RU2697383C2 (ru) Применение антагонистов il-17 для торможения прогрессирования структурных повреждений у пациентов с псориатическим артритом
US20220340668A1 (en) Treatment of liver disease or disorder comprising actrii receptor antagonists
JP7589045B2 (ja) リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法
KR20250131771A (ko) 트랜스티레틴-매개 아밀로이드증의 치료 또는 예방 방법
KR20230091885A (ko) 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)로 암을 치료하는 방법
CN117500827A (zh) 用于治疗皮肌炎（dm）的抗c5抗体的剂量和施用
CN116322765A (zh) 用于用奥瑞珠单抗治疗多发性硬化症的方法
HK40105291B (en) Method for diagnosing and treating partial lipodystrophy
HK40105291A (en) Method for diagnosing and treating partial lipodystrophy
Iniesta-Navalon et al. Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease
WO2018203289A1 (en) Methods of selectively treating asthma using il-17 antagonists
US20110104153A1 (en) Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
US20240301058A1 (en) Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
Sylow et al. Proteomic and phospho-proteomic longitudinal signatures of human skeletal muscle in lung cancer cachexia
Sørensen et al. Proteomic and phospho-proteomic longitudinal signatures of human skeletal muscle in lung cancer cachexia
CN117440827A (zh) 使用抗cd19抗体治疗重症肌无力
CN121311244A (zh) 抗blys抗体的新用途
Lacomis et al. What's in the Literature?

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260626

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260714

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260716